Literature DB >> 15341688

Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Matthew R Weir1.   

Abstract

Entities:  

Year:  2004        PMID： 15341688     DOI： 10.1007/s11906-004-0055-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  11 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Authors:  T W Gress; F J Nieto; E Shahar; M R Wofford; F L Brancati
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

4.  Ramipril and the development of diabetes.

Authors:  S Yusuf; H Gerstein; B Hoogwerf; J Pogue; J Bosch; B H Wolffenbuttel; B Zinman
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

5.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

Authors:  M J Brown; C R Palmer; A Castaigne; P W de Leeuw; G Mancia; T Rosenthal; L M Ruilope
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 8.  Diabetes, impaired glucose tolerance and insulin resistance with diuretics.

Authors:  L E Ramsay; W W Yeo; P R Jackson
Journal:  Eur Heart J       Date:  1992-12       Impact factor: 29.983

9.  Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus.

Authors:  J H Gurwitz; R L Bohn; R J Glynn; M Monane; H Mogun; J Avorn
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

10.  Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Claudia Borgioni; Roberto Gattobigio; Lucia Filippucci; Silvia Norgiolini; Costanza Bracco; Carlo Porcellati
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190
View more
  1 in total

1.  A High Triglyceride-Glucose Index Value Is Associated With an Increased Risk of Carotid Plaque Burden in Subjects With Prediabetes and New-Onset Type 2 Diabetes: A Real-World Study.

Authors:  Zhen-Zhen Jiang; Jian-Bo Zhu; Hua-Liang Shen; Shan-Shan Zhao; Yun-Yi Tang; Shao-Qi Tang; Xia-Tian Liu; Tian-An Jiang
Journal:  Front Cardiovasc Med       Date:  2022-03-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.